HomeComparePRVB vs SPHD

PRVB vs SPHD: Dividend Comparison 2026

PRVB yields 8.01% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRVB wins by $7.5K in total portfolio value
10 years
PRVB
PRVB
● Live price
8.01%
Share price
$24.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$1,328.87
Full PRVB calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — PRVB vs SPHD

📍 PRVB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRVBSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRVB + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRVB pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRVB
Annual income on $10K today (after 15% tax)
$680.54/yr
After 10yr DRIP, annual income (after tax)
$1,129.54/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, PRVB beats the other by $647.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRVB + SPHD for your $10,000?

PRVB: 50%SPHD: 50%
100% SPHD50/50100% PRVB
Portfolio after 10yr
$30.2K
Annual income
$948.11/yr
Blended yield
3.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PRVB right now

PRVB
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
8.7
Piotroski
2/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRVB buys
0
SPHD buys
0
No recent congressional trades found for PRVB or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRVBSPHD
Forward yield8.01%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$34.0K$26.5K
Annual income after 10y$1,328.87$567.37
Total dividends collected$10.7K$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PRVB vs SPHD ($10,000, DRIP)

YearPRVB PortfolioPRVB Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$11,501$800.64$11,130$430.50+$371.00PRVB
2$13,166$860.55$12,357$447.82+$809.00PRVB
3$15,009$920.73$13,687$464.65+$1.3KPRVB
4$17,040$980.90$15,126$480.98+$1.9KPRVB
5$19,274$1,040.82$16,682$496.78+$2.6KPRVB
6$21,723$1,100.23$18,362$512.03+$3.4KPRVB
7$24,403$1,158.93$20,174$526.72+$4.2KPRVB
8$27,328$1,216.71$22,127$540.84+$5.2KPRVB
9$30,514$1,273.41$24,230$554.39+$6.3KPRVB
10$33,979$1,328.87$26,493$567.37+$7.5KPRVB

PRVB vs SPHD: Complete Analysis 2026

PRVBStock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Full PRVB Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this PRVB vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRVB vs SCHDPRVB vs JEPIPRVB vs OPRVB vs KOPRVB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.